What happens when you take duloxetine with St. John's wort?
Duloxetine (Cymbalta, Drizalma Sprinkle) is a serotonin-norepinephrine reuptake inhibitor (SNRI) used for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, chronic musculoskeletal pain, and stress urinary incontinence (in some markets). It blocks both the serotonin and norepinephrine transporters at therapeutic doses. St. John's wort (Hypericum perforatum) is a botanical antidepressant whose active constituents, especially hyperforin, inhibit reuptake of serotonin, norepinephrine, and dopamine.
When the two are taken together, the additive blockade of serotonin reuptake (and to some extent norepinephrine reuptake) can raise synaptic monoamine levels into the danger zone for serotonin syndrome. Clinical features include altered mental status (agitation, confusion, hallucination), autonomic instability (tachycardia, hypertension, fever, sweating, dilated pupils, diarrhea), and neuromuscular hyperactivity (tremor, clonus that is often more pronounced in the lower extremities, hyperreflexia, rigidity). Severe cases can include hyperthermia above 40 degrees C, seizures, rhabdomyolysis, and death.
There is also a metabolic layer. St. John's wort is a strong inducer of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein. Duloxetine is metabolized primarily by CYP1A2 and to a lesser extent CYP2D6, so the most direct CYP3A4-induction effect on parent drug exposure is modest. However, hyperforin-mediated induction can alter overall hepatic processing and protein transport in ways that are difficult to predict, especially in patients on multiple co-administered drugs.
Why is this important?
Duloxetine is widely prescribed both in psychiatry and in pain medicine, so the patient population that may consider St. John's wort - people with chronic pain, fatigue, or low mood reaching for a natural supplement - overlaps heavily with people already on duloxetine. The supplement is sold over the counter and often does not appear on medication lists at clinic visits, so the interaction can go unrecognized.
Published case literature includes reports of patients presenting with confusion, autonomic instability, and other serotonin-syndrome features after combining SNRIs with St. John's wort. Major drug-interaction databases and the U.S. National Center for Complementary and Integrative Health (NCCIH) warn that combining St. John's wort with antidepressants, including SNRIs, can cause potentially life-threatening serotonin syndrome.
Duloxetine itself can cause autonomic side effects (sweating, blood pressure changes, tachycardia) and gastrointestinal effects (nausea, diarrhea) that overlap with early serotonin syndrome. Patients combining the two may attribute warning symptoms to medication side effects and continue both products, allowing the syndrome to escalate. Recognizing the constellation - especially clonus, hyperreflexia, and fever - is the most important step for clinicians.
Duloxetine should also not be combined with MAO inhibitors, and a washout of at least 14 days off an MAO inhibitor is required before starting duloxetine. The same caution principle applies to other strongly serotonergic agents such as St. John's wort.
What should you do?
If you take duloxetine, do not start St. John's wort. If you currently take both, contact your prescriber promptly. Do not stop duloxetine on your own - SNRI discontinuation can cause dizziness, electric-shock sensations, irritability, and flu-like symptoms. Seek emergency care if you have tremor, fever, fast heart rate, sweating, severe agitation, twitching, or muscle stiffness, and bring the supplement bottle.
If you and your prescriber decide to discontinue duloxetine, taper it under their guidance and allow at least one to two weeks of washout before introducing any new serotonergic agent. Most psychiatrists would not recommend swapping duloxetine for St. John's wort in moderate to severe depression or for pain indications - the evidence base for St. John's wort in pain conditions is weak, and its variable potency and CYP induction complicate any future medication choices.
Disclose every supplement, tea, and herbal product to your prescribing clinician and pharmacist. Be alert to St. John's wort in multi-ingredient blends labeled "mood," "stress," "sleep," "calm," or "women's wellness," and to its listing under Latin name (Hypericum perforatum) or regional names (Johanniskraut, millepertuis, hierba de San Juan).
Which specific products are affected?
This warning covers duloxetine in all branded and generic forms: Cymbalta, Drizalma Sprinkle, Irenka, and authorized generics. It applies whether duloxetine is being used for depression, anxiety, or any pain indication. On the supplement side, the warning applies to any Hypericum perforatum product: standardized extracts (often labeled 0.3% hypericin or 3-5% hyperforin), capsules, tablets, tinctures, teas, and combination products. Many over-the-counter sleep, mood, and "emotional support" blends contain St. John's wort.
Other serotonergic agents that compound risk include SSRIs, other SNRIs (venlafaxine, desvenlafaxine, milnacipran, levomilnacipran), tramadol, triptans, fentanyl, MDMA, dextromethorphan, linezolid, MAO inhibitors, lithium, tryptophan, and 5-HTP. Patients on duloxetine should treat any new serotonergic exposure as a discussion point with their prescriber.
The bottom line
Duloxetine plus St. John's wort is a high-risk combination that can cause serotonin syndrome and is flagged as a major or contraindicated interaction by NCCIH and standard drug-interaction references. If you take duloxetine for depression, anxiety, or pain, treat St. John's wort as off-limits and disclose every herbal product to your healthcare team.